Pathological Interface between Oligomeric Alpha-Synuclein and Tau in Synucleinopathies

Urmi Sengupta, Marcos J. Guerrero-Muñoz, Diana L. Castillo-Carranza, Cristian A. Lasagna-Reeves, Julia E. Gerson, Adriana A. Paulucci-Holthauzen, Shashirekha Krishnamurthy, Malika Farhed, George R. Jackson, Rakez Kayed

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Background Aberrant accumulation of α-synuclein constitutes inclusion bodies that are considered a characteristic feature of a group of neurological disorders described as synucleinopathies. Often, multiple disease-causing proteins overlap within a given disease pathology. An emerging body of research focuses on the oligomeric populations of various pathogenic proteins, considering them as the culprits causing neuronal damage and degeneration. To this end, the use of conformation-specific antibodies has proven to be an effective tool. Previous work from our laboratory and others has shown that oligomeric entities of α-synuclein and tau accumulate in their respective diseases, but their interrelationship at this higher order has yet to be shown in synucleinopathies. Methods Here, we used two novel conformation-specific antibodies, F8H7 and Syn33, which recognize α-synuclein oligomers and were developed in our laboratory. We investigated brain tissue from five of each Parkinson's disease and dementia with Lewy bodies patients by performing biophysical and biochemical assays using these antibodies, in addition to the previously characterized anti-tau oligomer antibody T22. Results We demonstrate that in addition to the deposition of oligomeric α-synuclein, tau oligomers accumulate in these diseased brains compared with control brains. Moreover, we observed that oligomers of tau and α-synuclein exist in the same aggregates, forming hybrid oligomers in these patients' brains. Conclusions In addition to the deposition of tau oligomers, our results also provide compelling evidence of co-occurrence of α-synuclein and tau into their most toxic forms, i.e., oligomers suggesting that these species interact and influence each other's aggregation via an interface in synucleinopathies.

Original languageEnglish (US)
Pages (from-to)672-683
Number of pages12
JournalBiological Psychiatry
Volume78
Issue number10
DOIs
StatePublished - Nov 15 2015

Fingerprint

Synucleins
alpha-Synuclein
Antibodies
Brain
Lewy Body Disease
Poisons
Inclusion Bodies
Brain Diseases
Nervous System Diseases
Parkinson Disease
Proteins
Pathology
Research

Keywords

  • Co-aggregation
  • Hybrid oligomers
  • Interaction
  • Synucleinopathy
  • Tau oligomers
  • α-Synuclein oligomers

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

Sengupta, U., Guerrero-Muñoz, M. J., Castillo-Carranza, D. L., Lasagna-Reeves, C. A., Gerson, J. E., Paulucci-Holthauzen, A. A., ... Kayed, R. (2015). Pathological Interface between Oligomeric Alpha-Synuclein and Tau in Synucleinopathies. Biological Psychiatry, 78(10), 672-683. https://doi.org/10.1016/j.biopsych.2014.12.019

Pathological Interface between Oligomeric Alpha-Synuclein and Tau in Synucleinopathies. / Sengupta, Urmi; Guerrero-Muñoz, Marcos J.; Castillo-Carranza, Diana L.; Lasagna-Reeves, Cristian A.; Gerson, Julia E.; Paulucci-Holthauzen, Adriana A.; Krishnamurthy, Shashirekha; Farhed, Malika; Jackson, George R.; Kayed, Rakez.

In: Biological Psychiatry, Vol. 78, No. 10, 15.11.2015, p. 672-683.

Research output: Contribution to journalArticle

Sengupta, U, Guerrero-Muñoz, MJ, Castillo-Carranza, DL, Lasagna-Reeves, CA, Gerson, JE, Paulucci-Holthauzen, AA, Krishnamurthy, S, Farhed, M, Jackson, GR & Kayed, R 2015, 'Pathological Interface between Oligomeric Alpha-Synuclein and Tau in Synucleinopathies', Biological Psychiatry, vol. 78, no. 10, pp. 672-683. https://doi.org/10.1016/j.biopsych.2014.12.019
Sengupta U, Guerrero-Muñoz MJ, Castillo-Carranza DL, Lasagna-Reeves CA, Gerson JE, Paulucci-Holthauzen AA et al. Pathological Interface between Oligomeric Alpha-Synuclein and Tau in Synucleinopathies. Biological Psychiatry. 2015 Nov 15;78(10):672-683. https://doi.org/10.1016/j.biopsych.2014.12.019
Sengupta, Urmi ; Guerrero-Muñoz, Marcos J. ; Castillo-Carranza, Diana L. ; Lasagna-Reeves, Cristian A. ; Gerson, Julia E. ; Paulucci-Holthauzen, Adriana A. ; Krishnamurthy, Shashirekha ; Farhed, Malika ; Jackson, George R. ; Kayed, Rakez. / Pathological Interface between Oligomeric Alpha-Synuclein and Tau in Synucleinopathies. In: Biological Psychiatry. 2015 ; Vol. 78, No. 10. pp. 672-683.
@article{add5abf0612649118a57477705ad5101,
title = "Pathological Interface between Oligomeric Alpha-Synuclein and Tau in Synucleinopathies",
abstract = "Background Aberrant accumulation of α-synuclein constitutes inclusion bodies that are considered a characteristic feature of a group of neurological disorders described as synucleinopathies. Often, multiple disease-causing proteins overlap within a given disease pathology. An emerging body of research focuses on the oligomeric populations of various pathogenic proteins, considering them as the culprits causing neuronal damage and degeneration. To this end, the use of conformation-specific antibodies has proven to be an effective tool. Previous work from our laboratory and others has shown that oligomeric entities of α-synuclein and tau accumulate in their respective diseases, but their interrelationship at this higher order has yet to be shown in synucleinopathies. Methods Here, we used two novel conformation-specific antibodies, F8H7 and Syn33, which recognize α-synuclein oligomers and were developed in our laboratory. We investigated brain tissue from five of each Parkinson's disease and dementia with Lewy bodies patients by performing biophysical and biochemical assays using these antibodies, in addition to the previously characterized anti-tau oligomer antibody T22. Results We demonstrate that in addition to the deposition of oligomeric α-synuclein, tau oligomers accumulate in these diseased brains compared with control brains. Moreover, we observed that oligomers of tau and α-synuclein exist in the same aggregates, forming hybrid oligomers in these patients' brains. Conclusions In addition to the deposition of tau oligomers, our results also provide compelling evidence of co-occurrence of α-synuclein and tau into their most toxic forms, i.e., oligomers suggesting that these species interact and influence each other's aggregation via an interface in synucleinopathies.",
keywords = "Co-aggregation, Hybrid oligomers, Interaction, Synucleinopathy, Tau oligomers, α-Synuclein oligomers",
author = "Urmi Sengupta and Guerrero-Mu{\~n}oz, {Marcos J.} and Castillo-Carranza, {Diana L.} and Lasagna-Reeves, {Cristian A.} and Gerson, {Julia E.} and Paulucci-Holthauzen, {Adriana A.} and Shashirekha Krishnamurthy and Malika Farhed and Jackson, {George R.} and Rakez Kayed",
year = "2015",
month = "11",
day = "15",
doi = "10.1016/j.biopsych.2014.12.019",
language = "English (US)",
volume = "78",
pages = "672--683",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "10",

}

TY - JOUR

T1 - Pathological Interface between Oligomeric Alpha-Synuclein and Tau in Synucleinopathies

AU - Sengupta, Urmi

AU - Guerrero-Muñoz, Marcos J.

AU - Castillo-Carranza, Diana L.

AU - Lasagna-Reeves, Cristian A.

AU - Gerson, Julia E.

AU - Paulucci-Holthauzen, Adriana A.

AU - Krishnamurthy, Shashirekha

AU - Farhed, Malika

AU - Jackson, George R.

AU - Kayed, Rakez

PY - 2015/11/15

Y1 - 2015/11/15

N2 - Background Aberrant accumulation of α-synuclein constitutes inclusion bodies that are considered a characteristic feature of a group of neurological disorders described as synucleinopathies. Often, multiple disease-causing proteins overlap within a given disease pathology. An emerging body of research focuses on the oligomeric populations of various pathogenic proteins, considering them as the culprits causing neuronal damage and degeneration. To this end, the use of conformation-specific antibodies has proven to be an effective tool. Previous work from our laboratory and others has shown that oligomeric entities of α-synuclein and tau accumulate in their respective diseases, but their interrelationship at this higher order has yet to be shown in synucleinopathies. Methods Here, we used two novel conformation-specific antibodies, F8H7 and Syn33, which recognize α-synuclein oligomers and were developed in our laboratory. We investigated brain tissue from five of each Parkinson's disease and dementia with Lewy bodies patients by performing biophysical and biochemical assays using these antibodies, in addition to the previously characterized anti-tau oligomer antibody T22. Results We demonstrate that in addition to the deposition of oligomeric α-synuclein, tau oligomers accumulate in these diseased brains compared with control brains. Moreover, we observed that oligomers of tau and α-synuclein exist in the same aggregates, forming hybrid oligomers in these patients' brains. Conclusions In addition to the deposition of tau oligomers, our results also provide compelling evidence of co-occurrence of α-synuclein and tau into their most toxic forms, i.e., oligomers suggesting that these species interact and influence each other's aggregation via an interface in synucleinopathies.

AB - Background Aberrant accumulation of α-synuclein constitutes inclusion bodies that are considered a characteristic feature of a group of neurological disorders described as synucleinopathies. Often, multiple disease-causing proteins overlap within a given disease pathology. An emerging body of research focuses on the oligomeric populations of various pathogenic proteins, considering them as the culprits causing neuronal damage and degeneration. To this end, the use of conformation-specific antibodies has proven to be an effective tool. Previous work from our laboratory and others has shown that oligomeric entities of α-synuclein and tau accumulate in their respective diseases, but their interrelationship at this higher order has yet to be shown in synucleinopathies. Methods Here, we used two novel conformation-specific antibodies, F8H7 and Syn33, which recognize α-synuclein oligomers and were developed in our laboratory. We investigated brain tissue from five of each Parkinson's disease and dementia with Lewy bodies patients by performing biophysical and biochemical assays using these antibodies, in addition to the previously characterized anti-tau oligomer antibody T22. Results We demonstrate that in addition to the deposition of oligomeric α-synuclein, tau oligomers accumulate in these diseased brains compared with control brains. Moreover, we observed that oligomers of tau and α-synuclein exist in the same aggregates, forming hybrid oligomers in these patients' brains. Conclusions In addition to the deposition of tau oligomers, our results also provide compelling evidence of co-occurrence of α-synuclein and tau into their most toxic forms, i.e., oligomers suggesting that these species interact and influence each other's aggregation via an interface in synucleinopathies.

KW - Co-aggregation

KW - Hybrid oligomers

KW - Interaction

KW - Synucleinopathy

KW - Tau oligomers

KW - α-Synuclein oligomers

UR - http://www.scopus.com/inward/record.url?scp=84940894409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940894409&partnerID=8YFLogxK

U2 - 10.1016/j.biopsych.2014.12.019

DO - 10.1016/j.biopsych.2014.12.019

M3 - Article

C2 - 25676491

AN - SCOPUS:84940894409

VL - 78

SP - 672

EP - 683

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 10

ER -